Ceritinib/Ceritinib: Positioning and Characteristics of Several Generations of Targeted Drugs

Ceritinib is a second-generation ALK inhibitor and is mainly used to treat ALK-positive advanced non-small cell lung cancer (NSCLC). Compared with the first-generation ALK inhibitor crizotinib, ceritinib has stronger ALK inhibitory ability and can penetrate the blood-brain barrier more effectively, so it has better efficacy in patients with brain metastases. The development of ALK-targeted drugs can be divided into three generations:

1. First generation (crizotinib, Crizotinib): Crizotinib is the world's first ALK inhibitor, opening an era of targeted therapy for ALK-positive lung cancer. However, due to drug resistance issues, many patients develop disease progression after 1-2 years of treatment, and crizotinib has weak control over brain metastases, so more potent second-generation drugs are needed.

2. Second generation (ceritinib, alectinib, brigatinib): Ceritinib, as a second generationALK inhibitor, is effective against crizotinib-resistant mutations (such as L1196M) and can better control brain metastasis. In addition, second-generation drugs such as alectinib and brigatinib also show higher PFS (progression-free survival), becoming better treatment options.

3. The third generation (lorlatinib, Lorlatinib): When resistance to second-generation drugs develops, the third-generation ALK inhibitor lorlatinib (Lorlatinib) becomes the key choice. It can overcome multiple drug-resistant mutations and has outstanding efficacy in CNS metastasis. Currently, lorlatinib has been approved by the FDA for the treatment of resistance to second-generation ALK drugs.

Ceritinib, as a second-generation ALK inhibitor, provides an effective treatment option after crizotinib resistance, especially for patients with brain metastases. However, with the launch of alectinib, brigatinib and lorlatinib, the market position of ceritinib has been challenged. In clinical practice, doctors usually select appropriate ALK inhibitors on a personalized basis based on the patient's drug resistance, brain metastasis status, and financial burden.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib